Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIA Study of ABC294640 in the Treatment of Patients With Advanced, Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma

Trial Profile

A Phase IIA Study of ABC294640 in the Treatment of Patients With Advanced, Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2018

At a glance

  • Drugs Opaganib (Primary)
  • Indications Cholangiocarcinoma
  • Focus Therapeutic Use
  • Sponsors RedHill Biopharma
  • Most Recent Events

    • 28 Nov 2018 Planned number of patients changed from 39 to 70.
    • 06 Sep 2018 According to a RedHill Biopharma media release, the study has achieved its pre-specified efficacy goal for the first stage of the two-stage study design, and will continue to its second stage will continue to its second stage. Enrollment of all subjects is expected to be completed by mid-2019.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top